<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><!-- InstanceBegin template="/Templates/templateIBC.dwt" codeOutsideHTMLIsLocked="false" -->
<head><!-- InstanceBeginEditable name="Head" -->
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<title>Ian Boyd Consulting - Services</title>
<link href="twoColElsLtHdr.css" rel="stylesheet" type="text/css" />
<!--[if IE]>
<style type="text/css"> 
/* place css fixes for all versions of IE in this conditional comment */
.twoColElsLtHdr #sidebar1 { padding-top: 30px; }
.twoColElsLtHdr #mainContent { zoom: 1; padding-top: 15px; }
/* the above proprietary zoom property gives IE the hasLayout it needs to avoid several bugs */
.twoColElsLtHdr #mainContent { left: 191px; }
</style>
<![endif]-->
<script type="text/javascript">
<!--
function MM_showHideLayers() { //v9.0
  var i,p,v,obj,args=MM_showHideLayers.arguments;
  for (i=0; i<(args.length-2); i+=3) 
  with (document) if (getElementById && ((obj=getElementById(args[i]))!=null)) { v=args[i+2];
    if (obj.style) { obj=obj.style; v=(v=='show')?'visible':(v=='hide')?'hidden':v; }
    obj.visibility=v; }
}
//-->
</script>
<!-- InstanceEndEditable -->
</head>
<body class="twoColElsLtHdr">
<div id="container">
  <div id="header">
    <div id="siteImage"><img src="images/siteImage.gif" alt="Image of Pills" width="190" height="142" /></div>
    <h1 class="siteHeading">ian boyd consulting<span class="siteHeadingTail">.com.au</span></h1>
    <h2 class="siteHeadingTagLine">Providing pharmacovigilance expertise</h2>
    <!-- end #header -->
  </div>
  
  <div id="blackLine"></div>
  <div id="sidebar1">
    <p><a href="/index.html">services</a></p>
    <p><a href="biography/default.html">biography</a></p>
    <p><a href="publications/default.html">publications</a></p>
    <p><a href="contact/default.html">contact</a></p>
    <!-- InstanceBeginEditable name="Page Image" -->
    <div id="image"><img src="images/servicesImage.jpg" alt="Image of a form" width="190" height="143" /></div>
    <!-- InstanceEndEditable --></div>
  <!-- InstanceBeginEditable name="Main Body" -->
  <div id="mainContent">
    <div id="signalDetection"> One of the major tasks of the Adverse Drug Reactions Unit of the TGA was the  detection of signals and Ian Boyd was involved in most of the important ones  over the past 20 years. Many of these can be seen in the list of publications  and they include major issues such as the association of jaundice with  flucloxacillin, jaundice and amoxicillin-clavulanate, the “triple whammy” and  bisphosphonates and osteonecrosis. Ian can assist in any signal detection  issue.</div>
    
    <div id="signalEvaluation">In addition to its role in signal detection, the Adverse Drug Reactions Unit of the TGA evaluated each signal. Ian Boyd was involved in most of these evaluations. Included in such evaluations were case-control studies, drug utilisation studies, case series investigations and risk factor analyses. Ian can provide expertise in signal evaluation in all situations. In addition to medicines, he has substantial experience in the evaluation of vaccine signal evaluation.</div>
    
    <div id="riskDetection">Ian Boyd has been involved in the preparation of a number of risk management plans for drugs entering the European market. Ian can take responsibility for the safety specification, the pharmacovigilance plan, an evaluation of the need for risk minimisation activities, a risk minimisation plan, or the complete risk management plan.</div>
    
    <div id="periodicSafety">Review of PSURs is an essential aspect of any regulatory agency and Ian has had substantial experience in this area. He can provide expertise in the preparation or review of PSURs.</div>
    
    <div id="safetyLabelling">Analysis and review of safety labelling in the product information or SPC of drugs is another essential aspect of any regulatory agency. Ian has substantial experience in the identification of safety issues and modifications to safety labelling to comply with regulatory requirements and can assist in minor or major projects in this area.</div>
    
    <div id="development">Ian has been involved in a number of major projects requiring the development of core safety information and can assist in the implementation of strategies to facilitate such development or can undertake major or minor projects in this area.</div>
    
    <div id="safetyIssues">One of Ian’s major tasks within the TGA was the review of safety issues and he has produced hundreds of reviews for consideration by Australia’s independent advisory body, the Adverse Drug Reactions Advisory Committee (ADRAC). Ian also has substantial experience in the area of vaccine safety. He can provide reviews of safety issues for both drugs and vaccines.</div>
    
    <div id="training">Ian has been involved in a number of training courses conducted by the TGA. In particular, he was a presenter and instructor in the joint TGA/Uppsala Monitoring Centre course held in 2002 and 2004, and in the 2004 version of this course, he was the deputy coordinator and assisted in the development of all aspects of the course. In addition, to presenting course lectures, he also ran a course in causality assessment during both of these international courses.</div>
    <h2> Services</h2>
    <p>Ian Boyd Consulting can assist in all aspects of  pharmacovigilance and drug safety including (<span style="font-style: italic">rollover each heading to read a description of each service</span>):</p>
    <blockquote>
      <p><a href="#", onmouseover="MM_showHideLayers('signalDetection','','show')" onmouseout="MM_showHideLayers('signalDetection','','hide')">Signal detection</a></p>
      <p>
        <noscript>
        One of the major tasks of the Adverse Drug Reactions Unit of the TGA was the detection of signals and Ian Boyd was involved in most of the important ones over the past 20 years. Many of these can be seen in the list of publications and they include major issues such as the association of jaundice with flucloxacillin, jaundice and amoxicillin-clavulanate, the “triple whammy” and bisphosphonates and osteonecrosis. Ian can assist in any signal detection issue.
        </noscript>
      </p>
      <p><a href="#" onmouseover="MM_showHideLayers('signalEvaluation','','show')" onmouseout="MM_showHideLayers('signalEvaluation','','hide')">Signal evaluation</a></p>
      <p>
        <noscript>
        In addition to its role in signal detection, the Adverse Drug Reactions Unit of the TGA evaluated each signal. Ian Boyd was involved in most of these evaluations. Included in such evaluations were case-control studies, drug utilisation studies, case series investigations and risk factor analyses. Ian can provide expertise in signal evaluation in all situations. In addition to medicines, he has substantial experience in the evaluation of vaccine signal evaluation.
        </noscript>
      </p>
      <p><a href="#" onmouseover="MM_showHideLayers('riskDetection','','show')" onmouseout="MM_showHideLayers('riskDetection','','hide')">Risk management/pharmacovigilance plans</a></p>
      <p>
        <noscript>
        Ian Boyd has been involved in the preparation of a number of risk management plans for drugs entering the European market. Ian can take responsibility for the safety specification, the pharmacovigilance plan, an evaluation of the need for risk minimisation activities, a risk minimisation plan, or the complete risk management plan.
        </noscript>
      </p>
      <p><a href="#" onmouseover="MM_showHideLayers('periodicSafety','','show')" onmouseout="MM_showHideLayers('periodicSafety','','hide')">Periodic Safety Update Reports (PSURs)</a></p>
      <p>
        <noscript>
        Review of PSURs is an essential aspect of any regulatory agency and Ian has had substantial experience in this area. He can provide expertise in the preparation or review of PSURs.
        </noscript>
      </p>
      <p><a href="#" onmouseover="MM_showHideLayers('safetyLabelling','','show')" onmouseout="MM_showHideLayers('safetyLabelling','','hide')">Safety labelling/product information/SPC reviews</a></p>
      <p>
        <noscript>
        Analysis and review of safety labelling in the product information or SPC of drugs is another essential aspect of any regulatory agency. Ian has substantial experience in the identification of safety issues and modifications to safety labelling to comply with regulatory requirements and can assist in minor or major projects in this area.
        </noscript>
      </p>
      <p><a href="#" onmouseover="MM_showHideLayers('development','','show')" onmouseout="MM_showHideLayers('development','','hide')">Development of core safety information</a></p>
      <p>
        <noscript>
        Ian has been involved in a number of major projects requiring the development of core safety information and can assist in the implementation of strategies to facilitate such development or can undertake major or minor projects in this area.
        </noscript>
      </p>
      <p><a href="#" onmouseover="MM_showHideLayers('safetyIssues','','show')" onmouseout="MM_showHideLayers('safetyIssues','','hide')">Review of safety issues</a></p>
      <p>
        <noscript>
        One of Ian’s major tasks within the TGA was the review of safety issues and he has produced hundreds of reviews for consideration by Australia’s independent advisory body, the Adverse Drug Reactions Advisory Committee (ADRAC). Ian also has substantial experience in the area of vaccine safety. He can provide reviews of safety issues for both drugs and vaccines.
        </noscript>
      </p>
      <p><a href="#" onmouseover="MM_showHideLayers('training','','show')" onmouseout="MM_showHideLayers('training','','hide')">Pharmacovigilance training</a></p>
      <p>
        <noscript>
        Ian has been involved in a number of training courses conducted by the TGA. In particular, he was a presenter and instructor in the joint TGA/Uppsala Monitoring Centre course held in 2002 and 2004, and in the 2004 version of this course, he was the deputy coordinator and assisted in the development of all aspects of the course. In addition, to presenting course lectures, he also ran a course in causality assessment during both of these international courses.
        </noscript>
        </p>
    </blockquote>
    <!-- end #mainContent -->
  </div>
  <!-- InstanceEndEditable -->
  <!-- This clearing element should immediately follow the #mainContent div in order to force the #container div to contain all child floats -->
  <br class="clearfloat" />
  <div id="footer">
    <p class="footer">&copy; 2015 Ian Boyd Consulting | ABN 19 968 328 424 | p/f +61 2 4455 4136 | <a href="mailto:ian@ianboydconsulting.com.au">ian@ianboydconsulting.com.au</a></p>
    <!-- end #footer -->
  </div>
  <!-- end #container -->
</div>
</body>
<!-- InstanceEnd --></html>
